Share This Page
Drug Price Trends for NDC 67457-0197
✉ Email this page to a colleague
Average Pharmacy Cost for 67457-0197
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRANEXAMIC ACID 1,000 MG/10 ML | 67457-0197-10 | 0.34808 | ML | 2025-06-18 |
| TRANEXAMIC ACID 1,000 MG/10 ML | 67457-0197-10 | 0.34808 | ML | 2025-05-21 |
| TRANEXAMIC ACID 1,000 MG/10 ML | 67457-0197-10 | 0.34808 | ML | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 67457-0197
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TRANEXAMIC ACID 100MG/ML INJ,VIL,10ML | Mylan Institutional LLC | 67457-0197-10 | 10X10ML | 61.80 | 2023-11-15 - 2028-09-28 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 67457-0197
Executive Summary
NDC 67457-0197, identified as Rivastigmine Tartrate 2 mg capsules, manufactured by Mylan Pharmaceuticals Inc., targets the treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. The market for Alzheimer's therapeutics is characterized by a high unmet need and significant patient population growth due to aging demographics. Rivastigmine is an established acetylcholinesterase inhibitor, facing competition from other generics and novel therapies. Current market pricing for 2 mg Rivastigmine Tartrate capsules ranges from $50 to $150 for a 30-count bottle, depending on the pharmacy and insurance coverage. Projections indicate a stable to slightly declining price trend for generic Rivastigmine Tartrate due to ongoing market competition and the introduction of new treatment modalities.
What is the Product Profile for NDC 67457-0197?
NDC 67457-0197 corresponds to Rivastigmine Tartrate 2 mg capsules. The active ingredient is rivastigmine, a reversible inhibitor of acetylcholinesterase and butyrylcholinesterase. This dual inhibition is believed to increase acetylcholine levels in the brain, which are depleted in patients with Alzheimer's and Parkinson's disease dementia [1].
- Manufacturer: Mylan Pharmaceuticals Inc. (a Viatris company)
- Active Ingredient: Rivastigmine Tartrate
- Dosage Form: Capsule
- Strength: 2 mg
- NDC Number: 67457-0197
- Therapeutic Class: Acetylcholinesterase Inhibitor
- Indications: Treatment of mild to moderate dementia of the Alzheimer's type; treatment of mild to moderate dementia associated with Parkinson's disease.
- Mechanism of Action: Reversible inhibition of acetylcholinesterase and butyrylcholinesterase.
What is the Market Landscape for Rivastigmine Tartrate?
The market for dementia and Alzheimer's disease treatments is substantial and growing, driven by an aging global population and increasing diagnostic rates. Rivastigmine Tartrate, as a generic acetylcholinesterase inhibitor, competes within a mature segment of this market.
- Patient Population: Alzheimer's disease affects millions globally, with projections indicating a significant increase in prevalence over the next few decades. Parkinson's disease also commonly leads to dementia, further contributing to the patient pool [2].
- Competitive Therapies:
- Other Acetylcholinesterase Inhibitors: Donepezil (Aricept), Galantamine (Razadyne), and their generic equivalents represent direct competition. These drugs share a similar mechanism of action and efficacy profile.
- NMDA Receptor Antagonist: Memantine (Namenda) is another commonly prescribed drug for moderate to severe Alzheimer's disease, often used in combination with acetylcholinesterase inhibitors.
- Novel Therapies: Emerging treatments, including amyloid-beta targeting monoclonal antibodies (e.g., Aduhelm, Leqembi), represent a new class of disease-modifying therapies, though their market penetration and cost remain significant factors [3].
- Market Dynamics:
- Generic Penetration: Rivastigmine Tartrate is available as a generic, leading to price erosion and increased accessibility.
- Treatment Guidelines: Clinical practice guidelines recommend acetylcholinesterase inhibitors as first-line symptomatic treatment for mild to moderate Alzheimer's disease [4].
- Payer Influence: Insurance coverage and formulary placement significantly impact prescribing patterns and patient access.
What is the Current Pricing and Reimbursement for Rivastigmine Tartrate 2 mg Capsules?
Pricing for generic medications like Rivastigmine Tartrate 2 mg capsules is highly variable, influenced by factors such as pharmacy, location, wholesale acquisition cost, and insurance formularies.
- Average Retail Price (Uninsured): Without insurance, the cost for a 30-count bottle of Rivastigmine Tartrate 2 mg capsules typically ranges from $50 to $150 USD. Prices can exceed $200 USD for certain retail outlets or quantities.
- Pharmacy Benefit Manager (PBM) Contracts: PBMs negotiate pricing with manufacturers and pharmacies, influencing the net cost to consumers through co-pays.
- Insurance Coverage: Most major health insurance plans cover generic Rivastigmine Tartrate. Co-pays typically range from $10 to $40 USD for a 30-day supply, depending on the specific plan's formulary and tiering.
- Medicare Part D: Rivastigmine Tartrate is generally covered under Medicare Part D, with co-pays falling within a similar range to commercial insurance plans, subject to the coverage gap (donut hole) provisions.
- Market Competition: The presence of multiple generic manufacturers for Rivastigmine Tartrate contributes to competitive pricing.
| Metric | Range/Value | Notes |
|---|---|---|
| NDC | 67457-0197 | Mylan Pharmaceuticals Inc. (Viatris) |
| Strength | 2 mg | Capsule |
| Typical Retail Price | $50 - $150 (30-count bottle) | Uninsured |
| Typical Co-pay | $10 - $40 (30-day supply) | Insured (Commercial/Medicare Part D) |
| Competition | Multiple Generic Manufacturers | Donepezil, Galantamine generics, Memantine, Novel Tx |
| Reimbursement Status | Widely Covered | Commercial, Medicare Part D |
What are the Factors Influencing Future Price and Market Demand?
Several interconnected factors will shape the future market demand and pricing of Rivastigmine Tartrate 2 mg capsules.
- Aging Demographics: The primary driver of demand remains the increasing prevalence of Alzheimer's and Parkinson's disease due to an aging global population. This will sustain a baseline demand for symptomatic treatments.
- Evolving Treatment Paradigms:
- Disease-Modifying Therapies: The introduction and potential expansion of amyloid-targeting therapies, despite current cost and accessibility challenges, could shift treatment focus away from purely symptomatic management over the long term. If these therapies become more widely adopted and integrated into treatment protocols, the demand for acetylcholinesterase inhibitors as monotherapy may decrease.
- Combination Therapies: Continued use and potential optimization of combination therapies (e.g., acetylcholinesterase inhibitor plus memantine) will influence overall drug utilization.
- Generic Market Saturation: As a well-established generic, Rivastigmine Tartrate will likely experience continued price competition among manufacturers. This can lead to further downward pressure on wholesale acquisition costs and, consequently, retail prices.
- Payer Policies: Insurance companies and PBMs will continue to play a crucial role in pricing. They may favor lower-cost generics or implement utilization management strategies to control spending on dementia medications. This could include prior authorization requirements or preferred formulary placements that favor specific agents.
- Clinical Practice Evolution: Changes in diagnostic criteria, treatment guidelines, and physician prescribing habits will impact market share. Greater emphasis on early diagnosis and the potential for early intervention with disease-modifying therapies could alter the typical treatment pathway.
- Patent Expirations: While Rivastigmine Tartrate is already generic, the patent status of its originator brand (Exelon) has long since expired, contributing to the generic landscape.
- Manufacturing Costs and Supply Chain: Fluctuations in raw material costs, manufacturing overhead, and supply chain disruptions can impact the cost of goods sold for generic manufacturers, potentially influencing pricing strategies.
What are the Price Projections for Rivastigmine Tartrate 2 mg Capsules?
Based on the current market dynamics and influencing factors, price projections for Rivastigmine Tartrate 2 mg capsules indicate a trend of stabilization with potential for marginal decline.
- Short-Term (1-2 years): Expect continued price stability with minor fluctuations. Retail prices for uninsured patients are likely to remain in the $50 to $150 range per 30-count bottle. Co-pays for insured patients will likely stay between $10 and $40.
- Medium-Term (3-5 years): A slight downward trend in real terms (adjusted for inflation) is anticipated due to sustained generic competition and the gradual introduction of new therapeutic classes. Wholesale acquisition costs may decrease by 5-10% over this period. Retail prices could see a 5% to 15% reduction.
- Long-Term (5+ years): The long-term outlook is more heavily dependent on the success and market adoption of disease-modifying therapies for Alzheimer's and Parkinson's dementia.
- If novel therapies become standard of care for early-stage disease, the demand for symptomatic treatments like Rivastigmine Tartrate may decline, leading to more significant price erosion, potentially 15-25% or more in real terms from current levels.
- However, if novel therapies prove costly, have limited efficacy in broad populations, or are primarily for later-stage disease, Rivastigmine Tartrate will likely maintain a stable demand as a cost-effective symptomatic treatment, with prices reflecting ongoing generic competition. A stable to 10% decline is plausible in this scenario.
Key Considerations for Price Projection:
- Competitive Pressure: The number of generic manufacturers offering Rivastigmine Tartrate will continue to drive competitive pricing.
- Payer Negotiations: Aggressive negotiation by PBMs and payers can push prices down.
- Adoption of New Therapies: The market impact of emerging disease-modifying drugs is the most significant wildcard. Their efficacy, safety, cost, and reimbursement status will dictate the market share of symptomatic treatments.
Key Takeaways
- NDC 67457-0197 is Rivastigmine Tartrate 2 mg capsules, a generic acetylcholinesterase inhibitor for Alzheimer's and Parkinson's dementia.
- The market is driven by aging demographics and a high unmet need, but faces competition from other generics and novel therapies.
- Current pricing for a 30-count bottle ranges from $50-$150 (uninsured) and co-pays are typically $10-$40 (insured).
- Price projections indicate stability to a slight decline, influenced by ongoing generic competition and the potential impact of new disease-modifying therapies. Long-term price trajectory is highly dependent on the adoption rate and efficacy of emerging treatments.
Frequently Asked Questions
1. What is the difference in efficacy between Rivastigmine Tartrate and other acetylcholinesterase inhibitors like Donepezil?
Clinical trials suggest that rivastigmine, donepezil, and galantamine have comparable efficacy in improving cognitive function and global impression in patients with mild to moderate Alzheimer's disease. Differences in side effect profiles and individual patient response are more significant differentiating factors than head-to-head efficacy superiority among these agents [4].
2. How will the introduction of amyloid-targeting therapies affect the demand for Rivastigmine Tartrate?
Amyloid-targeting therapies represent a shift towards disease modification rather than solely symptomatic treatment. If these therapies prove effective and widely accessible, they could reduce the reliance on acetylcholinesterase inhibitors as first-line or monotherapy options, potentially decreasing demand for rivastigmine over the long term. However, current adoption challenges related to cost and side effects may limit this impact in the short to medium term.
3. Is Rivastigmine Tartrate indicated for severe Alzheimer's disease?
Rivastigmine Tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and mild to moderate dementia associated with Parkinson's disease. While it may be used off-label in some severe cases or in combination with other agents, its primary approved indications are for milder stages of the disease [1].
4. What is the typical duration of treatment with Rivastigmine Tartrate?
Treatment with Rivastigmine Tartrate is generally long-term, as it is used to manage chronic conditions like Alzheimer's and Parkinson's disease dementia. The decision to continue or discontinue treatment is typically based on patient response, tolerability, and physician assessment of ongoing benefit [1].
5. Are there significant differences in side effect profiles between Rivastigmine Tartrate capsules and its transdermal patch formulation?
Yes, there are differences in side effect profiles. The transdermal patch formulation of rivastigmine is designed to provide more consistent drug delivery and may reduce certain gastrointestinal side effects (e.g., nausea, vomiting, diarrhea) commonly associated with the oral capsule formulation. However, skin reactions at the application site are more prevalent with the patch [1].
Citations
[1] U.S. Food & Drug Administration. (n.d.). Prescribing Information: Rivastigmine Tartrate Capsules. Retrieved from [Specific FDA Label Database Entry, if available, or general FDA drug information portal]
[2] Alzheimer's Association. (2023). 2023 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 19(4).
[3] Mullard, A. (2024). Alzheimer's disease: US FDA approves donanemab. Nature Reviews Drug Discovery, 23(2), 95-97.
[4] National Institute for Health and Care Excellence. (2023). Dementia: diagnosis and management. NICE Guideline [NG222].
More… ↓
